Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Label Expansion of Braftovi, Augtyro, Lunsumio SC Up for MHLW Panel Review
October 16, 2025
- Vyloy Braced for Price Cut after Cost-Effectiveness Assessment
October 16, 2025
- Komeito’s Exit from Ruling Coalition Casts Uncertainty over Japan’s Drug Policy
October 15, 2025
- Japan to Continue Subsidies for Domestic Biosimilar Production: MHLW Official
October 15, 2025
- MHLW to Clarify Criteria for Japanese PI Waivers through Q&A, Calls for Data-Based Justifications
October 14, 2025
- Japan’s Healthcare Spending Reaches 48.1 Trillion Yen in FY2023
October 14, 2025
- PMDA Lays Out AI Action Plan, Eyes Specialized In-House System
October 14, 2025
- MHLW Panel OKs 19th Edition of Japanese Pharmacopoeia; 27 New Products Added
October 14, 2025
- MHLW Maps Out Action Plan to Tackle Drug Supply Disruptions
October 14, 2025
- Eto to Stay as LDP Pharma Study Group Chair Even After Exiting Politics
October 10, 2025
- GS1 Barcode Adoption Stalls at 40% of Hospitals, Pharmacist Urges Subsidies
October 10, 2025
- MHLW to Disclose Review Reports for Conditionally Cleared Regenerative Therapies Even If Full Approval Bid Dropped
October 10, 2025
- Japan Launches Study on Legal Framework for Patent Linkage System
October 9, 2025
- Chuikyo Frowns on Industry Calls for Scrapping Huge-Seller Re-Pricing, Spillovers
October 9, 2025
- Chuikyo Wary of Revising “Zero” Premium Rule for Low Cost Disclosure
October 9, 2025
- Komeito Calls for Careful Study of Re-Pricing Rules for CAR-T Therapies
October 9, 2025
- Elevidys Coverage Debate to Resume after MHLW Gains Broad Understanding on Safety
October 9, 2025
- Japan Begins Overhaul of Patent Linkage Framework with First Notification
October 8, 2025
- Japan Panel OKs Basic Policy for Stockpiling Crisis-Response Medicines
October 8, 2025
- Turn Sakaguchi’s Nobel-Winning Research into Societal Impact: LDP Panel Chief
October 8, 2025
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…